Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113860 | 0.94 | PPARG (0.52) | PPARGFFAR4P2RX3FFAR1RAB9A | |
| SCHEMBL5106677 | 0.90 | PPARG (0.51) | PPARGFFAR4P2RX3FFAR1MRGPRX4 | |
| SCHEMBL5106954 | 0.87 | PPARG (0.49) | PPARGFFAR4P2RX3FFAR1MRGPRX4 | |
| SCHEMBL5118952 | 0.84 | PPARG (0.47) | PPARGFFAR4P2RX3FFAR1MRGPRX4 | |
| SCHEMBL5112547 | 0.82 | PPARG (0.46) | PPARGFFAR4P2RX3FFAR1RAB9A | |
| SCHEMBL5107321 | 0.80 | PPARG (0.59) | PPARG | |
| SCHEMBL5120342 | 0.79 | FFAR4 (0.48) | PPARGFFAR4P2RX3FFAR1MRGPRX4 | |
| SCHEMBL5112205 | 0.79 | MAPT (0.43) | PPARGFFAR4FFAR1MRGPRX4RAB9A | |
| SCHEMBL5114324 | 0.78 | MAPT (0.44) | PPARGFFAR4FFAR1MRGPRX4RAB9A | |
| SCHEMBL5106147 | 0.76 | P2RX3 (0.46) | PPARGFFAR4P2RX3FFAR1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885FFAR4 91/4885P2RX3 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.